Vertebrobasilar thrombolysis with intravenous tirofiban: Case report

The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolys...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2002-04, Vol.13 (2), p.81-84
Main Authors: LIEBESKIND, David S, POLLARD, John R, SCHWARTZ, Eric D, CUCCHIARA, Brett L, MCGARVEY, Michael L, HURST, Robert W
Format: Article
Language:English
Subjects:
Aged
Arterial Occlusive Diseases - complications
Arterial Occlusive Diseases - drug therapy
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Hemorrhage - chemically induced
Hemorrhage - prevention & control
Humans
Male
Medical sciences
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - adverse effects
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Stroke - complications
Stroke - drug therapy
Thrombolytic Therapy - adverse effects
Thrombolytic Therapy - methods
Treatment Outcome
Tyrosine - administration & dosage
Tyrosine - adverse effects
Tyrosine - analogs & derivatives
Vertebrobasilar Insufficiency - complications
Vertebrobasilar Insufficiency - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 84
container_issue 2
container_start_page 81
container_title Journal of thrombosis and thrombolysis
container_volume 13
creator LIEBESKIND, David S
POLLARD, John R
SCHWARTZ, Eric D
CUCCHIARA, Brett L
MCGARVEY, Michael L
HURST, Robert W
description The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolysis with intravenous tirofiban, a selective platelet glycoprotein IIb/IIIa receptor antagonist, and discuss the potential thrombolytic properties of this class of antithrombotics.
doi_str_mv 10.1023/A:1016242713327
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_220346594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>387020071</sourcerecordid><originalsourceid>FETCH-LOGICAL-p264t-6e2ceb737c180211e493df2ff583599e76f269af63a292886eabe782c44aa3483</originalsourceid><addsrcrecordid>eNpFz89LwzAUB_AgipvTszcpgsdq8l6aNLvJ_AkDLyreStolLKNrapIq--8tOPH0Lp_ve99HyDmj14wC3tzOGWUCOEiGCPKATFkhMZccPg7JlCpQeYG0mJCTGDeUUqUoHJMJgzGGJZ-Su3cTkqmDr3V0rQ5ZWge_rX27iy5m3y6tM9eloL9M54eYJRe8dbXu5tlCR5MF0_uQTsmR1W00Z_s5I28P96-Lp3z58vi8uF3mPQiecmGgMbVE2bCSAmOGK1xZsLYosVDKSGFBKG0FalBQlsLo2sgSGs61Rl7ijFz-7u2D_xxMTNXGD6EbT1YAFLkoFB_RxR4N9dasqj64rQ676u_nEVztgY6Nbm3QXePiv8OxHFCJPyjCZUM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220346594</pqid></control><display><type>article</type><title>Vertebrobasilar thrombolysis with intravenous tirofiban: Case report</title><source>Springer Link</source><creator>LIEBESKIND, David S ; POLLARD, John R ; SCHWARTZ, Eric D ; CUCCHIARA, Brett L ; MCGARVEY, Michael L ; HURST, Robert W</creator><creatorcontrib>LIEBESKIND, David S ; POLLARD, John R ; SCHWARTZ, Eric D ; CUCCHIARA, Brett L ; MCGARVEY, Michael L ; HURST, Robert W</creatorcontrib><description>The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolysis with intravenous tirofiban, a selective platelet glycoprotein IIb/IIIa receptor antagonist, and discuss the potential thrombolytic properties of this class of antithrombotics.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1023/A:1016242713327</identifier><identifier>PMID: 12101384</identifier><identifier>CODEN: JTTHFF</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject><![CDATA[Aged ; Arterial Occlusive Diseases - complications ; Arterial Occlusive Diseases - drug therapy ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Fibrinolytic Agents - administration & dosage ; Fibrinolytic Agents - adverse effects ; Hemorrhage - chemically induced ; Hemorrhage - prevention & control ; Humans ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors ; Stroke - complications ; Stroke - drug therapy ; Thrombolytic Therapy - adverse effects ; Thrombolytic Therapy - methods ; Treatment Outcome ; Tyrosine - administration & dosage ; Tyrosine - adverse effects ; Tyrosine - analogs & derivatives ; Vertebrobasilar Insufficiency - complications ; Vertebrobasilar Insufficiency - drug therapy]]></subject><ispartof>Journal of thrombosis and thrombolysis, 2002-04, Vol.13 (2), p.81-84</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Apr 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13802207$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12101384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LIEBESKIND, David S</creatorcontrib><creatorcontrib>POLLARD, John R</creatorcontrib><creatorcontrib>SCHWARTZ, Eric D</creatorcontrib><creatorcontrib>CUCCHIARA, Brett L</creatorcontrib><creatorcontrib>MCGARVEY, Michael L</creatorcontrib><creatorcontrib>HURST, Robert W</creatorcontrib><title>Vertebrobasilar thrombolysis with intravenous tirofiban: Case report</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><description>The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolysis with intravenous tirofiban, a selective platelet glycoprotein IIb/IIIa receptor antagonist, and discuss the potential thrombolytic properties of this class of antithrombotics.</description><subject>Aged</subject><subject>Arterial Occlusive Diseases - complications</subject><subject>Arterial Occlusive Diseases - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Fibrinolytic Agents - administration &amp; dosage</subject><subject>Fibrinolytic Agents - adverse effects</subject><subject>Hemorrhage - chemically induced</subject><subject>Hemorrhage - prevention &amp; control</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - administration &amp; dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists &amp; inhibitors</subject><subject>Stroke - complications</subject><subject>Stroke - drug therapy</subject><subject>Thrombolytic Therapy - adverse effects</subject><subject>Thrombolytic Therapy - methods</subject><subject>Treatment Outcome</subject><subject>Tyrosine - administration &amp; dosage</subject><subject>Tyrosine - adverse effects</subject><subject>Tyrosine - analogs &amp; derivatives</subject><subject>Vertebrobasilar Insufficiency - complications</subject><subject>Vertebrobasilar Insufficiency - drug therapy</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpFz89LwzAUB_AgipvTszcpgsdq8l6aNLvJ_AkDLyreStolLKNrapIq--8tOPH0Lp_ve99HyDmj14wC3tzOGWUCOEiGCPKATFkhMZccPg7JlCpQeYG0mJCTGDeUUqUoHJMJgzGGJZ-Su3cTkqmDr3V0rQ5ZWge_rX27iy5m3y6tM9eloL9M54eYJRe8dbXu5tlCR5MF0_uQTsmR1W00Z_s5I28P96-Lp3z58vi8uF3mPQiecmGgMbVE2bCSAmOGK1xZsLYosVDKSGFBKG0FalBQlsLo2sgSGs61Rl7ijFz-7u2D_xxMTNXGD6EbT1YAFLkoFB_RxR4N9dasqj64rQ676u_nEVztgY6Nbm3QXePiv8OxHFCJPyjCZUM</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>LIEBESKIND, David S</creator><creator>POLLARD, John R</creator><creator>SCHWARTZ, Eric D</creator><creator>CUCCHIARA, Brett L</creator><creator>MCGARVEY, Michael L</creator><creator>HURST, Robert W</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20020401</creationdate><title>Vertebrobasilar thrombolysis with intravenous tirofiban: Case report</title><author>LIEBESKIND, David S ; POLLARD, John R ; SCHWARTZ, Eric D ; CUCCHIARA, Brett L ; MCGARVEY, Michael L ; HURST, Robert W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p264t-6e2ceb737c180211e493df2ff583599e76f269af63a292886eabe782c44aa3483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Arterial Occlusive Diseases - complications</topic><topic>Arterial Occlusive Diseases - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Fibrinolytic Agents - administration &amp; dosage</topic><topic>Fibrinolytic Agents - adverse effects</topic><topic>Hemorrhage - chemically induced</topic><topic>Hemorrhage - prevention &amp; control</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - administration &amp; dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists &amp; inhibitors</topic><topic>Stroke - complications</topic><topic>Stroke - drug therapy</topic><topic>Thrombolytic Therapy - adverse effects</topic><topic>Thrombolytic Therapy - methods</topic><topic>Treatment Outcome</topic><topic>Tyrosine - administration &amp; dosage</topic><topic>Tyrosine - adverse effects</topic><topic>Tyrosine - analogs &amp; derivatives</topic><topic>Vertebrobasilar Insufficiency - complications</topic><topic>Vertebrobasilar Insufficiency - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LIEBESKIND, David S</creatorcontrib><creatorcontrib>POLLARD, John R</creatorcontrib><creatorcontrib>SCHWARTZ, Eric D</creatorcontrib><creatorcontrib>CUCCHIARA, Brett L</creatorcontrib><creatorcontrib>MCGARVEY, Michael L</creatorcontrib><creatorcontrib>HURST, Robert W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LIEBESKIND, David S</au><au>POLLARD, John R</au><au>SCHWARTZ, Eric D</au><au>CUCCHIARA, Brett L</au><au>MCGARVEY, Michael L</au><au>HURST, Robert W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vertebrobasilar thrombolysis with intravenous tirofiban: Case report</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><addtitle>J Thromb Thrombolysis</addtitle><date>2002-04-01</date><risdate>2002</risdate><volume>13</volume><issue>2</issue><spage>81</spage><epage>84</epage><pages>81-84</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><coden>JTTHFF</coden><abstract>The use of thrombolytic agents in the setting of established cerebral infarction is limited by concerns for hemorrhagic transformation. Novel thrombolytic approaches, which have received minimal consideration, may be associated with lower risks of hemorrhage. We illustrate vertebrobasilar thrombolysis with intravenous tirofiban, a selective platelet glycoprotein IIb/IIIa receptor antagonist, and discuss the potential thrombolytic properties of this class of antithrombotics.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>12101384</pmid><doi>10.1023/A:1016242713327</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0929-5305
ispartof Journal of thrombosis and thrombolysis, 2002-04, Vol.13 (2), p.81-84
issn 0929-5305
1573-742X
language eng
recordid cdi_proquest_journals_220346594
source Springer Link
subjects Aged
Arterial Occlusive Diseases - complications
Arterial Occlusive Diseases - drug therapy
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Hemorrhage - chemically induced
Hemorrhage - prevention & control
Humans
Male
Medical sciences
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - adverse effects
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Stroke - complications
Stroke - drug therapy
Thrombolytic Therapy - adverse effects
Thrombolytic Therapy - methods
Treatment Outcome
Tyrosine - administration & dosage
Tyrosine - adverse effects
Tyrosine - analogs & derivatives
Vertebrobasilar Insufficiency - complications
Vertebrobasilar Insufficiency - drug therapy
title Vertebrobasilar thrombolysis with intravenous tirofiban: Case report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A31%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vertebrobasilar%20thrombolysis%20with%20intravenous%20tirofiban:%20Case%20report&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=LIEBESKIND,%20David%20S&rft.date=2002-04-01&rft.volume=13&rft.issue=2&rft.spage=81&rft.epage=84&rft.pages=81-84&rft.issn=0929-5305&rft.eissn=1573-742X&rft.coden=JTTHFF&rft_id=info:doi/10.1023/A:1016242713327&rft_dat=%3Cproquest_pubme%3E387020071%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p264t-6e2ceb737c180211e493df2ff583599e76f269af63a292886eabe782c44aa3483%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=220346594&rft_id=info:pmid/12101384&rfr_iscdi=true